Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Precision BioSciences a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene...

Vyondys 53: What Does FDA Rejection Letter Mean?

The Food and Drug Administration published more than 200 letters it sent to companies after their medications were rejected...

Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients

Due to two documented incidents of severe liver failure that resulted in death, Sarepta Therapeutics has stopped shipping its...